Sylentis, S.A.

Quick facts

Phase 3 pipeline

• SYL1001 ophthalmic solution · Ophthalmology
  SYL1001 is a small interfering RNA (siRNA) that silences the production of transforming growth factor-beta 2 (TGF-β2) to reduce intraocular pressure in glaucoma.
• Tivanisiran sodium ophthalmic solution · Ophthalmology
  Tivanisiran sodium ophthalmic solution is an antisense oligonucleotide that targets the SOD1 gene to reduce the production of superoxide dismutase 1 protein.

Phase 2 pipeline

• SYL040012
• SYL1001
• SYL1801

Phase 1 pipeline

• SYL18001 sodium High dose b.i.d
• SYL18001 sodium High dose q.d
• SYL18001 sodium Low dose q.d
• SYL18001 sodium Middle dose q.d

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sylentis, S.A. portfolio CI brief
• Sylentis, S.A. pipeline updates RSS